Ferhina Ali, MD
Retina Specialist · Valhalla, NYNPI 1245552447
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 27.3% of the total. Reporting peaked in 2024 at $71,929 and has fallen 70.3% since, to $21,394 in 2025. Among retina specialist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $732.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$48K
- Astellas Pharma US Inc$35K
- Genentech USA, Inc.$34K
- AbbVie$17K
- Eyepoint US, Inc.$11K
- Genentech, Inc.$9K
- plus $23K from 13 others
Across 63 payments — averaging $664.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$33K
- Regeneron$9K
What the payments were for
- Consulting fees$78,08844%
- Speaking & faculty fees$80,73846%
- Travel & lodging$8,3815%
- Food & beverage$9,2135%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 37 | $48,165 |
| Astellas Pharma US Inc | 31 | $34,869 |
| Genentech USA, Inc. | 43 | $33,600 |
| AbbVie(2 entities) | 40 | $16,896 |
| Eyepoint US, Inc. | 21 | $11,100 |
| Genentech, Inc. | 13 | $9,049 |
| Regeneron Healthcare Solutions, Inc. | 12 | $7,435 |
| Regeneron | 7 | $4,856 |
| F. Hoffmann-la Roche AG | 3 | $4,637 |
| Ocular Therapeutix, Inc. | 6 | $4,241 |
| Bausch & Lomb Americas Inc. | 9 | $934 |
| Alimera Sciences, Inc. | 7 | $309 |
| Alcon | 3 | $76 |
| Amgen | 2 | $56 |
| Novartis | 3 | $56 |
| Neurotech Pharmaceuticals, Inc. | 1 | $54 |
| Astellas US LLC | 1 | $51 |
| Dutch Ophthalmic, USA | 1 | $17 |
| Biogen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$176,420 in reported general payments places this provider in the 95th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 31 | $1,694 |
| Trazodone Hcl | 39 | $565 |
| Ketorolac Tromethamine | 15 | $412 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $225 |
| Sertraline Hcl | 12 | $198 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Valhalla
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
- Sarwar ZahidJackson Heights$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.